Amicus Therapeutics, Inc. (NASDAQ:FOLD) Insider Sells $424,095.48 in Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) insider Ellen Rosenberg sold 31,839 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, January 24th. The shares were sold at an average price of $13.32, for a total value of $424,095.48. Following the transaction, the insider now owns 332,345 shares of the company’s stock, valued at $4,426,835.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Amicus Therapeutics Price Performance

FOLD traded down $0.17 during trading on Wednesday, hitting $13.22. The company’s stock had a trading volume of 1,303,502 shares, compared to its average volume of 2,343,194. The company has a current ratio of 2.78, a quick ratio of 2.70 and a debt-to-equity ratio of 2.95. Amicus Therapeutics, Inc. has a twelve month low of $5.91 and a twelve month high of $13.61. The business’s fifty day simple moving average is $12.02 and its 200 day simple moving average is $11.36. The firm has a market capitalization of $3.71 billion, a price-to-earnings ratio of -14.37 and a beta of 0.88.

Amicus Therapeutics (NASDAQ:FOLD – Get Rating) last issued its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.07. Amicus Therapeutics had a negative return on equity of 123.94% and a negative net margin of 81.65%. The company had revenue of $81.69 million for the quarter, compared to analyst estimates of $84.55 million. On average, equities research analysts forecast that Amicus Therapeutics, Inc. will post -0.78 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on FOLD. Morgan Stanley lifted their price target on Amicus Therapeutics from $14.00 to $15.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 8th. StockNews.com upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, December 31st. Finally, BTIG Research raised their price objective on Amicus Therapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a report on Wednesday, January 18th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Institutional Trading of Amicus Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Park Avenue Securities LLC acquired a new stake in shares of Amicus Therapeutics in the fourth quarter worth approximately $129,000. Wedge Capital Management L L P NC acquired a new stake in shares of Amicus Therapeutics in the fourth quarter worth approximately $2,795,000. Fulton Bank N.A. acquired a new stake in shares of Amicus Therapeutics in the fourth quarter worth approximately $144,000. Bank of New York Mellon Corp boosted its stake in shares of Amicus Therapeutics by 4.8% in the third quarter. Bank of New York Mellon Corp now owns 1,229,564 shares of the biopharmaceutical company’s stock worth $12,837,000 after acquiring an additional 55,838 shares during the last quarter. Finally, Ambassador Advisors LLC acquired a new stake in shares of Amicus Therapeutics in the third quarter worth approximately $3,301,000.

About Amicus Therapeutics

(Get Rating)

Amicus Therapeutics, Inc operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio.